title: High frequency of thrombocytopenia in patients with acute-on-chronic liver failure treated with linezolid.
abstract: BACKGROUND
  Linezolid is an effective antibiotic reagent for Gram-positive bacterial infection; its most common side effect is thrombocytopenia. However, the incidence of thrombocytopenia in patients with acute-on-chronic liver failure (ACLF) who underwent linezolid therapy was unclear. The present study was to evaluate the incidence of thrombocytopenia in ACLF and non-ACLF patients treated with linezolid and the risk factors of thrombocytopenia in these patients.
  
  
  METHODS
  Thirty-five patients with ACLF who had been subjected to intravenous administration of 600 mg linezolid every 12 hours for more than 7 days were categorized as a ACLF treatment (ACLF-T) group, 72 patients without ACLF treated with the same dosage of linezolid were recruited as a non-ACLF treatment (NACLF-T) group, and 70 patients with ACLF without linezolid treatment served as an ACLF control (ACLF-C) group. The incidences of thrombocytopenia in different groups were compared at day 14. Risk factors were investigated using logistic regression analysis.
  
  
  RESULTS
  The incidence of thrombocytopenia at day 14 was significantly higher in the ACLF-T group than in the ACLF-C group (20/35 vs 24/70, P=0.025) and in the NACLF-T group (20/35 vs 9/72, P<0.001). Multivariate analysis showed that the ratio of platelet count (day 7/day 0)<1 (OR=10.021; P=0.012) and the baseline platelet count (OR=0.985; P=0.036) were independent risk factors of thrombocytopenia at day 14 of linezolid therapy.
  
  
  CONCLUSIONS
  The benefits of linezolid treatment should outweigh the risk of thrombocytopenia in patients with ACLF. Moreover, it is necessary to closely monitor the platelet count during linezolid therapy especially in the patients with decreased platelet count at day 7 of linezolid therapy.
authors.affiliation: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Department of Infectious Diseases, the First Affiliated Hospital, Zhejiang University School of Medicine; Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, Hangzhou 310003, China. ljli@zju.edu.cn.
authors.forename: Yi-Min
authors.initials: YM
authors.lastname: Zhang
authors.forename: Wei
authors.initials: W
authors.lastname: Yu
authors.forename: Ning
authors.initials: N
authors.lastname: Zhou
authors.forename: Jian-Zhou
authors.initials: JZ
authors.lastname: Li
authors.forename: Li-Chen
authors.initials: LC
authors.lastname: Xu
authors.forename: Zhong-Yang
authors.initials: ZY
authors.lastname: Xie
authors.forename: Ying-Feng
authors.initials: YF
authors.lastname: Lu
authors.forename: Lan-Juan
authors.initials: LJ
authors.lastname: Li
mesh_terms: D065290:Acute-On-Chronic Liver Failure / Q000175:diagnosis / Q000188:drug therapy*; D061605:Administration, Intravenous; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000009:adverse effects*; D016009:Chi-Square Distribution; D002681:China / Q000453:epidemiology; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015994:Incidence; D000069349:Linezolid / Q000008:administration & dosage / Q000009:adverse effects*; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D016017:Odds Ratio; D018579:Patient Selection; D010976:Platelet Count; D012189:Retrospective Studies; D012307:Risk Factors; D013921:Thrombocytopenia / Q000097:blood / Q000139:chemically induced* / Q000175:diagnosis / Q000453:epidemiology; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000900:Anti-Bacterial Agents; D000069349:Linezolid